Biogen (HAM:IDP) Short Percentage of Float


HAM:IDP Biogen Inc HAM:IDP
73 GF Score
Price €187.44
GF Value €166.45
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Biogen Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

HAM:IDP vs OGN, AMRN, SCLX: Short Percentage of Float Comparison

For the Drug Manufacturers - General subindustry, Biogen's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biogen Short Percentage of Float vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Biogen's Short Percentage of Float falls into.


HAM:IDP
73GF Score
Biogen Inc HAM:IDP
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biogen (HAM:IDP) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €187.44 is trading 12.6% above its estimated GF Value™ of €166.45. GuruFocus considers Biogen to be Modestly Overvalued.

Key valuation signals for HAM:IDP:

  • Short Percentage of Float:
  • GF Value™: €166.45 vs. price of €187.44 (12.6% above fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the HAM:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
73GF Score

Get the complete analysis for HAM:IDP

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€187.44
Price
€166.45
GF Value